Brief information on fondaparinux
- Fondaparinux (Arixtra) is a potent selective indirect inhibitor of factor Xa via activation of antithrombin III (ATIII).
- Approved for
thromboprophylaxis
in orthopedic surgery, treatment of DVT and
PE
- Subcutaneous
administration
- Prophylactic dose is 2.5 mg
once
daily, therapeutic dose is 5–10 mg once daily.
- No coagulation monitoring necessary
- Significantly
lower incidence of VTE compared to
enoxaparin
- There
are no specific antidotes against
fondaparinux
- Elimination half-life is 17–21 hours (and up to 72 hours depending on renal function).